| Document |
Document Title |
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/073755A2 |
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids ("BIAs") such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocod...
|
|
WO/2024/068683A1 |
A stationary phase for use in affinity chromatography for recovering adeno-associated virus (AAV) vectors (3) from a solution. The stationary phase comprises a porous polymer matrix (1) having a mean flow pore size of 0.1-2.0 µm, wherei...
|
|
WO/2024/065376A1 |
Disclosed in the present invention is the use of a differentially methylated region of callipyge gene in meat trait breeding. Disclosed in the present invention is a differentially methylated region from an imprinted region Dlk1-Mirg of ...
|
|
WO/2024/066026A1 |
Provided is a chimeric antigen receptor targeting IL13Rα2, comprising: (1) an optimized anti-IL13Rα2 scFv sequence; (2) an optimized hinge region/spacer region; (3) a transmembrane region (TM); (4) a CD28 costimulatory domain and a 4-1...
|
|
WO/2024/065959A1 |
Provided are a rape green revolution gene bgr and a use thereof. The gene bgr can significantly reduce the height of rape plants, achieve thick and strong stems, lodging resistance, a reduced branching angle, and a compact plant type, an...
|
|
WO/2024/068898A1 |
The present invention provides pre-mRNA trans-splicing molecules (RTMs) that are useful for correcting mutations in the OPA1 gene. Also provided are methods of using the RTMs as gene therapy (e.g., ex vivo and in vivo gene therapy) for t...
|
|
WO/2024/072890A1 |
Methods and materials involved in reducing the level of a long noncoding RNA of fat mass and obesity-associated protein (FTO-IT1) in a cell are provided herein.
|
|
WO/2024/071397A1 |
The present invention provides an IL13RA2-targeting herpes simplex virus in which an anti-IL13RA2 antibody or an antigen-binding fragment thereof is presented on the viral surface. Also provided is an anti-IL13RA2 antibody or an antigen-...
|
|
WO/2024/067344A1 |
The present invention relates to an antibody or an antigen-binding fragment for specifically recognizing LIGHT, a preparation method therefor, and use thereof.
|
|
WO/2024/072998A1 |
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin...
|
|
WO/2024/071956A1 |
The present invention relates to a fusion polypeptide and a method for purifying a target protein by using same, the polypeptide having any one from among a His tag, a HAT tag and an HQ tag, and an α-helix peptide tag of which the major...
|
|
WO/2024/072897A1 |
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In pa...
|
|
WO/2024/065297A1 |
Embodiments of the present invention provide a chimeric antigen receptor with a light chain variable region having a sequence set forth in SEQ ID NO: 1 and a heavy chain variable region having a sequence set forth in SEQ ID NO: 2. The ch...
|
|
WO/2024/073715A2 |
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant allele...
|
|
WO/2024/067759A1 |
The present invention relates to a novel humanized anti-human CLDN18.2 antibody and an antigen-binding fragment thereof. The present invention also relates to a preparation method for the antibody. The present invention further relates t...
|
|
WO/2024/073689A1 |
Synthetic polynucleotide libraries may include a plurality of polynucleotides. The polynucleotides may comprise DNA and may be configured to hybridize with one or more regions of target nucleic acids. The target nucleic acids may compris...
|
|
WO/2024/066819A1 |
Disclosed is a method for producing 3-hydroxypropionic acid and acrylic acid by means of fermentation. The present invention provides a recombinant Corynebacterium glutamicum. The aldehyde dehydrogenase gene ald of the microorganism is u...
|
|
WO/2024/072882A1 |
Provided herein are vectors including a polynucleotide encoding an α9L9'T protein, pharmaceutical compositions including the vector including a polynucleotide encoding an α9L9'T protein, and methods of use thereof. The methods of use i...
|
|
WO/2024/067821A1 |
Provided is a modified cell, wherein the modified cell is formed by binding a complex protein to a cell surface marker molecule of the modified cell. The complex protein comprises a part specifically binding to the cell surface marker mo...
|
|
WO/2024/065651A1 |
The present invention relates to a method for loading a dimer CD24 into an HEK293 cell exosome with ADAM10 gene knocked out. By means of loading a dimer CD24 and/or ApoE protein into an HEK293 cell exosome with ADAM10 gene knocked out, t...
|
|
WO/2024/072775A1 |
The present disclosure provides devices, systems, kits, and related methods for isolating DNA from a sample (e.g., plasma) using RNA-guided DNA binding proteins (e.g., Cas proteins). Particularly, the disclosure provides devices, systems...
|
|
WO/2024/073726A2 |
The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.
|
|
WO/2024/071279A1 |
Provided is a super-high-molecular gamma-polyglutamic acid having an average molecular weight of at least 20 million. Also provided is a Bacillus genus bacterium variant strain that can produce said super-high-molecular γ-PGA. Further p...
|
|
WO/2024/067747A1 |
The present invention provides a 5'-UTR sequence capable of improving the translation efficiency of a protein coding region, and a use thereof. The 5'-UTR sequence of the present invention can improve the translation efficiency of the pr...
|
|
WO/2024/071924A1 |
In one embodiment of the present invention, the present invention relates to an exosome and uses thereof, the exosome comprising a protein that induces cell death and a polypeptide that increases the half-life of an exosome. The exosome ...
|
|
WO/2024/067861A1 |
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, com...
|
|
WO/2024/067644A1 |
A method for cell-free preparation of an mRNA transcription template, the method comprising the following steps: 1) in the presence of at least one type of primer and while promoting the amplification of a DNA template, causing contact o...
|
|
WO/2024/065657A1 |
Embodiments of the present disclosure provide access control method and access control apparatus. The access control method for controlling access right of a person for entering a place physically may include: obtaining an identity infor...
|
|
WO/2024/073570A1 |
Provided are materials and methods for rejuvenating senescent cells. Senescent cells are transduced with a viral vector to express Oct4, Sox2, and Klf4 proteins for partial cell reprogramming and a dominant negative NFκBIA protein to su...
|
|
WO/2024/065268A1 |
Provided is a single-domain antibody or antigen-binding fragment capable of identifying ANG-2, and a multispecific antibody. The antibody or antigen-binding fragment has a heavy chain variable region as represented by any one of SEQ ID N...
|
|
WO/2024/069464A1 |
The present invention discloses a method to quantify tRNA abundance and tRNA modifications in an RNA sample that comprises contacting RNA with oligonucleotides in the presence of a ligating agent and performing nanopore direct sequencing...
|
|
WO/2024/067770A1 |
Provided is a lentivirus packaging titer kit. An existing virus packaging vector is modified to construct a high-virus packaging titer kit. For conventional virus helper plasmids, a replication origin, a promoter, a terminator, an enhanc...
|
|
WO/2024/066416A1 |
Provided are a CXCL-BPI fusion protein capable of being used for treating gram-negative bacterial infections, an encoding nucleic acid thereof, an expression and preparation method therefor, and use thereof for preparing a pharmaceutical...
|
|
WO/2024/067540A1 |
Disclosed is a genetically engineered HSV-1, comprising a deletion of an internal inverted repeat region, and a deletion in an HVEM binding domain of gD. The HSV-1 comprises a first polynucleotide encoding a Fc-less bispecific antibody i...
|
|
WO/2024/072820A1 |
In alternative embodiments, provided are compositions, including compositions, products of manufacture and kits, and methods, for manipulating, and in particular, augmenting or increasing, T cell activity in vitro and in vivo, by for exa...
|
|
WO/2024/065042A1 |
Provided are novel sulfur-containing lipids and nanoparticles containing such lipids and a cargo molecule, such as a nucleic acid, methods to formulate said lipids with nucleic acids to produce lipid nanoparticles and chemical routes for...
|
|
WO/2024/068754A1 |
The invention relates to a system (1) for continuous manufacture of biomolecules comprising feed tanks (2) suitable for storing products and a reaction chamber (4) designed to be fed with products from said feed tanks which form in the r...
|
|
WO/2024/073709A2 |
The technology described herein relates modified oligonucleotides and double-stranded RNAs, e.g., siRNAs, compositions and kits comprising them and methods of their use for inhibiting target genes.
|
|
WO/2024/073114A1 |
The present disclosure relates to compositions of matter and methods used to activate effector nucleic acids and effector targets in vivo via a CRISPR-based cascade system. The compositions and methods achieve non-specific delivery of ca...
|
|
WO/2024/067086A1 |
Provided is a Bacillus licheniformis cell capable of being stably and repeatedly used for conversion and synthesis of D-allulose, which belongs to the field of biotechnology. D-allulose is a functional sugar with a high health value and ...
|
|
WO/2024/071180A1 |
Provided is a novel carrier for introducing a protein such as a Cas protein into cells. A carrier for a protein according to the present invention is characterized by containing vesicles of the fruit of the Malpighiaceae plant, wherein...
|
|
WO/2024/069144A1 |
The invention provides means and methods for treating, preventing or reversing retinal degeneration by RNA editing. The methods comprise administering to the subject a vector or a pair of complementary vectors that express a dCaslS-ADARn...
|
|
WO/2024/067725A1 |
Provided are a respiratory syncytial virus subtype B (RSV-B) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer of the recombinant F protein, and an immunogenic compo...
|
|
WO/2024/071424A1 |
Provided is a vector or vector set for analyzing the function of a functional molecule, said vector or vector set comprising: a polynucleotide that codes for an expression system of a candidate molecule for the functional molecule; a pol...
|
|
WO/2024/071411A1 |
[Problem] To provide an immune cell induced from an iPS cell, to which a phenotype favorable to the migration or invasion of an immune cell to a solid tumor site and the proliferation and survive of an immune cell in a solid tumor is imp...
|
|
WO/2024/066780A1 |
Provided are a fusion type adeno-associated virus and a gene delivery effect thereof in the lung and eyes. The fusion type adeno-associated virus comprises a fusion peptide fragment formed by fusion of peptide fragments of serotype AAV1 ...
|
|
WO/2024/066083A1 |
The present invention relates to the technical field of biology, and in particular to a constant-temperature detection kit and detection method for detecting pathogens. The kit comprises an amplification system; the amplification system ...
|
|
WO/2024/073735A2 |
Provided herein are oligonucleotides (e.g., siRNA) targeting S6K1. Also provided are methods of treating a disease associated with S6K1 expression.
|
|
WO/2024/069581A1 |
Protein complexes including a cytidine deaminase and a helicase. In some embodiments, the cytidine deaminase is an altered cytidine deaminase. In some embodiments, the protein complex converts 5 methylcytosine to thymine. Kits, compositi...
|
